Aurobindo Pharma launches generic Advair Diskus for asthma and COPD in US

Lannett Company, part of Aurobindo Pharma, has launched generic Advair Diskus in the US, making it the first complex inhalation product from Aurobindo to be marketed there. This market is worth approximately $908 million. Moreover, Cipla's US branch has also obtained FDA approval for the same product, setting the stage for an exciting competition in respiratory treatments.